Elixir Pharmaceuticals, Inc.

Elixir Pharmaceuticals, Inc.

Elixir Pharmaceuticals concocts treatments targeting metabolic diseases and disorders. Dedicated to the discovery, development, and commercialization of treatments for such diseases as diabetes and obesity, the company has taken a dual approach to its work: licensing products from other pharmaceutical companies for development and pursuing proprietary products. Product candidates currently under development include Glinsuna and Metgluna as treatment for type 2 diabetes and a ghrelin antagonist as a treatment for a range of metabolic disorders (all in phase III testing). The company is also exploring the use of sirtuin modulators to treat metabolic disorders, cancer, and neurodegenerative disease.

Contact Details

Office Address

Elixir Pharmaceuticals, Inc.
300 Putnam Avenue
Cambridge, MA, UK 02139
Phone: (617) 995-7000
Fax: (617) 995-7050

Executives

Chairman

Vaughn M. Kailian

CEO and Chief Medical Officer

Paul M. (Kip) Martha

Business Reviews for Elixir Pharmaceuticals, Inc.

Related Companies